Quantitative MRI for Early Treatment Response in MASLD.
作者信息
Yin Meng
机构信息
Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
出版信息
Radiology. 2025 Aug;316(2):e252218. doi: 10.1148/radiol.252218.
Abstract
摘要
相似文献
1
Quantitative MRI for Early Treatment Response in MASLD.
Radiology. 2025 Aug;316(2):e252218. doi: 10.1148/radiol.252218.
2
Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.
Clin Nutr. 2024 Jul;43(7):1770-1781. doi: 10.1016/j.clnu.2024.05.042. Epub 2024 May 31.
3
Impact of alcohol consumption and muscle mass on bone mineral density in metabolic dysfunction and alcohol-associated liver disease (MetALD) and metabolic dysfunction-associated steatotic liver disease (MASLD).
Clin Nutr ESPEN. 2025 Jul 7;69:145-153. doi: 10.1016/j.clnesp.2025.07.002.
4
Screening for MASLD in patients with type 2 diabetes: is an early diagnosis a good diagnosis?
Expert Rev Gastroenterol Hepatol. 2025 Sep;19(9):941-951. doi: 10.1080/17474124.2025.2546597. Epub 2025 Aug 19.
6
Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001318.
7
Weight gain in infancy and metabolic dysfunction-associated steatotic liver disease (MASLD) in a prospective birth cohort of Latino children.
Matern Health Neonatol Perinatol. 2025 Aug 15;11(1):25. doi: 10.1186/s40748-025-00225-8.
8
(-)Epicatechin targets early growth response protein 1, an inflammation-associated ferroptosis regulator, to ameliorate metabolic dysfunction-associated steatotic liver disease.
Biochem Pharmacol. 2025 Jul 4;240:117100. doi: 10.1016/j.bcp.2025.117100.
9
Validation of FIB-4 for the Diagnosis of Liver Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Can Liver J. 2025 Feb 12;8(2):280-283. doi: 10.3138/canlivj-2024-0063. eCollection 2025 May.
10
Impact of weight loss and lifestyle modifications on liver fibrosis in MASLD and MetALD: A cohort study.
Biomed Rep. 2025 Jul 25;23(4):158. doi: 10.3892/br.2025.2036. eCollection 2025 Oct.
本文引用的文献
1
Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model.
Radiology. 2025 Aug;316(2):e243780. doi: 10.1148/radiol.243780.
2
Multi-Center, Multi-Vendor Validation of Simultaneous MRI-Based Proton Density Fat Fraction and R2* Mapping Using a Combined Proton Density Fat Fraction-R2* Phantom.
J Magn Reson Imaging. 2025 Apr 18. doi: 10.1002/jmri.29775.
3
Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Aliment Pharmacol Ther. 2025 Jul;62(1):22-32. doi: 10.1111/apt.70150. Epub 2025 Apr 10.
4
Three-Dimensional Vector MR Elastography for Evaluating Tissue Mechanical Heterogeneity to Assess Liver Disease Progression.
Radiology. 2025 Apr;315(1):e242349. doi: 10.1148/radiol.242349.
5
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective.
Aliment Pharmacol Ther. 2025 May;61(9):1467-1478. doi: 10.1111/apt.70020. Epub 2025 Feb 18.
6
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.
Hepatology. 2025 Jan 1;81(1):312-320. doi: 10.1097/HEP.0000000000001112. Epub 2024 Oct 18.
7
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
JHEP Rep. 2024 Jan 19;6(4):101011. doi: 10.1016/j.jhepr.2024.101011. eCollection 2024 Apr.
8
Computed tomography-based evaluation of segmental variation of liver density and its implications.
Indian J Gastroenterol. 2020 Feb;39(1):60-65. doi: 10.1007/s12664-019-01008-8. Epub 2020 Mar 10.
9
Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects.
J Magn Reson Imaging. 2014 May;39(5):1265-71. doi: 10.1002/jmri.24284. Epub 2013 Oct 17.
Zotero 插件